Evidence map›Paper›PMID 31734836›Full record

ReviewJournal of cancer research and clinical oncology2020

Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.

Masoud Najafi, Bagher Farhood, Keywan Mortezaee, Ebrahim Kharazinejad, Jamal Majidpoor, Reza Ahadi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masoud NajafiRadiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Bagher FarhoodDepartments of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Keywan MortezaeeCancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. Keywan987@yahoo.com.ORCID http://orcid.org/0000-0003-2004-3465
Ebrahim KharazinejadDepartment of Anatomy, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
Jamal MajidpoorDepartment of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Reza AhadiDepartment of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer stem cells (CSCs) are highly tumorigenic cell types that reside within specific areas of tumor microenvironment (TME), and are endowed with self-renewal and resistance properties. Here, we aimed to discuss mechanisms involved in hypoxia-derived CSC resistance and targeting for effective cancer therapy.

resultsPreferential localization within hypoxic niches would help CSCs develop adaptive mechanisms, mediated through the modification of responses to various stressors and, as a result, show a more aggressive behavior.

conclusionHypoxia, in fact, serves as a multi-tasking strategy to nurture CSCs with this adaptive capacity, complexing targeted therapies.

Indexed as

AnimalsCell HypoxiaCell PlasticityHumansNeoplasmsNeoplastic Stem CellsAdaptationCancer stem cell (CSC)HypoxiaHypoxia-inducible factor (HIF)ResistanceStemnessTumor microenvironment (TME)

Identifiers

PMID31734836
PMCPMC11804417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.